Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer

World Journal of Clinical Oncology

Volumn 6, Issue 4, 2015, Pages 64-72

  Shameem, Raji ^a   Hamid, Muhammad Saad ^b   Xu, Kevin Y ^c   Wu, Shenhong ^d,e  

^a FOX CHASE CANCER CENTER   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Abiraterone; Chemotherapy na ve; Docetaxel; Metastatic castration resistant prostate cancer; Post chemotherapy; Pre chemotherapy

Indexed keywords

EID: 84942590878     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v6.i4.64     Document Type: Review

References (27)

1. Tan PS, Haaland B, Montero AJ, Kyriakopoulos CE, Lopes G. Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel-an Indirect Comparison. Clin Med Insights Oncol 2014; 8: 29-36 [PMID: 24678245 DOI: 10.4137/CMO.S13671]
2. Ryan CJ, Molina A, Li J, Kheoh T, Small EJ, Haqq CM, Grant RP, de Bono JS, Scher HI. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol 2013; 31: 2791-2798 [PMID: 23816964 DOI: 10.1200/JCO.2012.45.4595]
3. Liu JJ, Zhang J. Sequencing systemic therapies in metastatic castration-resistant prostate cancer. Cancer Control 2013; 20: 181-187 [PMID: 23811702]
4. Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J. New agents for prostate cancer. Ann Oncol 2014; 25: 1700-1709 [PMID: 24658665 DOI: 10.1093/annonc/mdu038]
5. Huang X, Chau CH, Figg WD. Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. J Hematol Oncol 2012; 5: 35 [PMID: 22747660 DOI: 10.1186/1756-8722-5-35]
6. Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormonedependent and castration-resistant prostate cancer. Pharmacol Ther 2013; 140: 223-238 [PMID: 23859952 DOI: 10.1016/j.pharmthera. 2013.07.003]
7. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512 [PMID: 15470213 DOI: 10.1056/NEJMoa040720]
8. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520 [PMID: 15470214 DOI: 10.1056/NEJMoa041318]
9. Chi KN, Bjartell A, Dearnaley D, Saad F, Schröder FH, Sternberg C, Tombal B, Visakorpi T. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 2009; 56: 594-605 [PMID: 19560857 DOI: 10.1016/j.eururo.2009.06.027]
10. Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castrationresistant prostate cancer. Eur Urol 2014; 65: 1198-1204 [PMID: 23910941 DOI: 10.1016/j.eururo.2013.07.022]
11. Zhang TY, Agarwal N, Sonpavde G, DiLorenzo G, Bellmunt J, Vogelzang NJ. Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments. Curr Urol Rep 2013; 14: 174-183 [PMID: 23559076 DOI: 10.1007/s11934-013-0322-0]
12. Azad AA, Eigl BJ, Leibowitz-Amit R, Lester R, Kollmannsberger C, Murray N, Clayton R, Heng DY, Joshua AM, Chi KN. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015; 67: 441-447 [PMID: 24508071 DOI: 10.1016/j.eururo.2014.01.030]
13. Goyal J, Antonarakis ES. Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer. Clin Med Insights Urol 2013; 2013: 1-14 [PMID: 24482578 DOI: 10.4137/CMU.S8337]
14. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-148 [PMID: 23228172 DOI: 10.1056/NEJMoa1209096]
15. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13: 983-992 [PMID: 22995653 DOI: 10.1016/S1470-2045(12)70379-0]
16. El-Amm J, Aragon-Ching JB. The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol 2013; 5: 25-40 [PMID: 23323145 DOI: 10.1177/17588 34012458137]
17. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12 [PMID: 8721797 DOI: 10.1016/0197-2456(95)0013 4-4]
18. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159 [PMID: 18309951 DOI: 10.1200/JCO.2007.12.4487]
19. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247 [PMID: 19097774 DOI: 10.1016/j.ejca.2008.10.026]
20. Zhou ZR, Liu SX, Zhang TS, Xia J, Li B. Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev 2014; 15: 1313-1320 [PMID: 24606458 DOI: 10.7314/APJCP.2014.15.3.1313]
21. Morris MJ, Autio KA, Basch EM, Danila DC, Larson S, Scher HI. Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable? Semin Oncol 2013; 40: 375-392 [PMID: 23806501 DOI: 10.1053/j.seminoncol.2 013.04.008]
22. van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM. Crossresistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 2013; 49: 3821-3830 [PMID: 24200698 DOI: 10.1016/j.ejca.2013.09.026]
23. Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S, Thompson E, Hunt J, Sheridan E, Baikady B, Sarvadikar A, Maier G, Reid AH, Mulick Cassidy A, Olmos D, Attard G, de Bono J. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 2012; 23: 2943-2947 [PMID: 22771826 DOI: 10.1093/annonc/mds119]
24. Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrateresistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). Cancer 2013; 119: 3636-3643 [PMID: 23913744 DOI: 10.1002/cncr.28285]
25. Bahl A, Masson S, Birtle A, Chowdhury S, de Bono J. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents. Cancer Treat Rev 2014; 40: 170-177 [PMID: 23958310 DOI: 10.1016/j.ctrv.2013.06.008]
26. Asselah J, Sperlich C. Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: Questions of choice. Can Urol Assoc J 2013; 7: S11-S17 [PMID: 23682301]
27. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65: 467-479 [PMID: 24321502 DOI: 10.1016/j.eururo.2013.11.002]